OTC : CHMMF

Chimeric Therapeutics Limited

$0.1 USD

$0 (0.0%)

Volume
30K
Average Volume
19.04K
Market Capitalization
$4.1M
P/E Ratio
-0.08
Dividend Yield
0.00%
Price Target
Year High
$0.10
Year Low
$0.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.69
Company Overview

OTC

Rebecca McQualter

Biotechnology

Healthcare

CHMMF

5

AU

USD

https://www.chimerictherapeutics.com

61 3 9824 5254

N/A

N/A

Liquidity Metrics

0.00

0.69

0.69

0.34

0.00

Sales & Valuation

$3.97M

0.51

-0.47

-0.29

-0.19

Profitability

-$0.77

-$10.43M

-420.80%

-596.25%

2844.96%

-252.99%

P/E Metrics

-0.08

0.00

0.00

Analyst Price Target & Rating

Sell

2/5

0 Analysts

%

Poll Results

About Chimeric Therapeutics Limited (OTC:CHMMF) Stock

Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies. Another key program, CHM 1101 (a CLTX CAR T-cell therapy), is also in Phase I development, specifically targeting patients with recurrent or progressive glioblastoma that expresses MMP2. Beyond these lead programs, the company is actively developing a range of other innovative therapies. These include CHM 0301 for various blood cancers; CHM 1301 (CLTX C ... AR NK) and CHM 2301 (CDH17 CAR NK), both designed to combat solid tumors. The CLTX CAR T-cell therapy, CHM 1101, is additionally being explored for indications such as melanoma, colorectal, and prostate cancers. Furthermore, CHM 2101 (CDH17 CAR T) is under development for neuroendocrine, colorectal, pancreatic, and gastric cancers. Established in 2020, Chimeric Therapeutics Limited maintains its headquarters in Carlton, Australia.

Frequently Asked Questions

What is the current Chimeric Therapeutics Limited (CHMMF) stock price?

Chimeric Therapeutics Limited(OTC:CHMMF) stock price is $0.1 in the last trading session. During the trading session, CHMMF stock reached the peak price of $0.1 while $0.001 was the lowest point it dropped to. The percentage change in CHMMF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CHMMF stock was $0.

CHMMF's industry and sector of operation?

The OTC listed CHMMF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CHMMF?

Agathe Bourgogne | Head of Manufacturing
Stephanie H. Astrow | Chief Scientific Officer
Aaron Laurita | Chief Financial Officer
Rebecca McQualter | Chief Executive Officer
Nathan Jong | Joint Company Secretary

How many employees does CHMMF have?

Number of CHMMF employees currently stands at 5. CHMMF operates from 62 Lygon Street, Carlton, VIC 3053, AU.

Link for CHMMF official website?

Official Website of CHMMF is: https://www.chimerictherapeutics.com

How do I contact CHMMF?

CHMMF could be contacted at phone #61 3 9824 5254 and can also be accessed through its website. CHMMF operates from 62 Lygon Street, Carlton, VIC 3053, AU.

How many shares of CHMMF are traded daily?

The average number of CHMMF shares traded daily for last 3 months was 19.04K.

What is the market cap of CHMMF currently?

The market value of CHMMF currently stands at $4.1M with its latest stock price at $0.1